Nicholas Goldner, PhD
About Nicholas Goldner, PhD
Nicholas Goldner, PhD, is the Senior Vice President of Product Development at resistanceBio and a Venture Partner at Pioneer Fund. He co-founded and successfully exited Viosera Therapeutics, and holds a PhD in Molecular Cell Biology from Washington University in St. Louis.
Title
Nicholas Goldner, PhD, serves as the Senior Vice President of Product Development at resistanceBio. He holds multiple roles within the organization, including being a founder and previously serving as the Chief Executive Officer.
Professional Experience
Nicholas Goldner has an extensive background in the biotechnology industry. He is currently a Senior Vice President of Product Development and Chief Marketing Officer at resistanceBio, based in Menlo Park, California. Apart from his roles at resistanceBio, he serves as a Venture Partner at Pioneer Fund in the San Francisco Bay Area. Previously, he co-founded and led Viosera Therapeutics as CEO, successfully exiting to a large pharmaceutical company in 2022. Goldner has played pivotal roles in both operational and strategic capacities.
Educational Background
Nicholas Goldner earned a PhD in Molecular Cell Biology from Washington University in St. Louis, where he focused on the molecular basis of cell signaling and metabolism. Prior to this, he graduated with honors with a Bachelor of Science (BS) in Biochemistry from Wisconsin Lutheran College. His academic achievements provided a strong foundation for his subsequent career in biotechnology and entrepreneurial ventures.
Achievements
Throughout his career, Nicholas Goldner has accomplished notable achievements. His participation in Y Combinator in 2019 was instrumental in launching and accelerating the growth of Viosera Therapeutics. The successful exit of Viosera Therapeutics to a large pharmaceutical company in 2022 marked a significant milestone in his professional journey. Goldner's educational background and industry expertise have been pivotal to his professional successes.